Health Inc.

House Committee Says J&J Is Dragging Its Heels On Recall Probe

Two weeks after a contentious Capitol Hill hearing into Johnson & Johnson's quality problems with children's medicine, the chairman of a House panel says the company is hindering the investigation.

A box of Tylenol infants' drops

One of the medicines for children that Johnson & Johnson recalled in April. J&J hide caption

itoggle caption J&J

Rep. Edolphus Towns (D-NY) told the New York Times that J&J hadn't been forthcoming with the committee's investigation.

Other companies probed recently by the panel, including Bank of America and AIG, did a better job, he told the paper. "But we are not getting the kind of information and cooperation from Johnson that I would like," Towns told the Times.

In an e-mail to Shots, Bonnie Jacobs, a spokeswoman for J&J's McNeil unit, disputed that characterization:

We have been very cooperative with the Committee. We have provided about 20,000 pages of documents to the Committee. Every executive that the Committee asked to interview has been made available.

A spokeswoman for the House Committee on Oversight and Government Reform told us the "Chairman's comments stand."

At issue is how the company handled quality problems at a plant that made liquid medicines for kids, including Tylenol and Benadryl, and were recalled in late April. Another line of questioning concerns the company's handling of problems with adult-strength Motrin tablets and what the committee called a "phatom recall" of the medicines.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.